DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypochromic microcytic anemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypochromic microcytic anemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypochromic microcytic anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Microcytic hypochromic anaemia is defined by a mean corpuscular volume below 80 cu mu. A 1979 article notes that the condition is usually due to iron deficiency or chronic disease but may signify thalassemia minor, and that exact identification of the cause is important because inappropriate iron therapy may be useless or dangerous. No drug treatment is evaluated in that article.
A 2017 hospital-based observational study in Bengal examined 150 newly diagnosed cases of microcytic hypochromic anaemia using complete blood count, iron profile, and HPLC. Iron deficiency anaemia accounted for 90 cases (60%), anaemia of chronic disease for 31 cases (21%), and thalassaemia for 29 cases (19%). Iron deficiency was predominantly seen in women (84%) of reproductive age (31–40 years) and in pre- or post-menopausal women (41–50 years). Anaemia of chronic disease was found mostly in patients over 50 years, with a male predominance (74%). Thalassaemia cases were mostly male children (55%) aged 6–10 years. The study concludes that iron deficiency is the major cause of microcytic hypochromic anaemia in that population.
A 2024 observational study in Nalgonda included 44 children aged 1 to 11 years with microcytic hypochromic anaemia (42% male, 58% female). The authors state that anaemia is a symptom of another condition, not an illness in itself, and that finding the underlying cause is more important than the morphological diagnosis. They recommend special precautions to determine the cause of iron deficiency and to diagnose thalassaemia trait to avoid excessive iron supplementation and to enable family screening. No drug was tested or recommended.
Across these studies, no drug is proposed or tested for treating microcytic hypochromic anaemia. The research remains at the diagnostic classification stage. What is missing is any trial of a specific pharmacological intervention, any funding for such a trial, and any patient stratification beyond the broad categories of iron deficiency, chronic disease, and thalassaemia.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Postgraduate Medicine · 1979 · 2 citations
Investigation of microcytic anemia
AbstractThis article on microcytic anemia is the first of several on laboratory investigation of anemia. Microcytic anemia, characterized by a mean corpuscular volume of less than 80 cu mu, is usually due to iron deficiency or chronic disease but may signify thalassemia minor. Exact identification of the cause is important, since inappropriate iron therapy may be useless or even dangerous.
Journal of Medical Science And clinical Research · 2017 · 1 citations · open access
A Study on Microcytic Hypochromic Anaemia with the Help of Parameters: CBC with RBC Indices, Biochemical Markers (Iron Profile) and HPLC - A Hospital Based Observational Study
AbstractBackground of the study-Anaemia is a common problem woridwide ,specially in the developing countries and amidst rural population. Microcytic hypochromic anemia is more prevalent clinicopathological subtype which is found in our day to day practice. In our study we have a humble effort to find out the major etiological factors behind this microcytic hypochromic anemia in a hospital based study on rural and urban Bengal. Aims and Objective-To find out the major etiological factor behind the microcytic hypochromic anemia with the help of complete blood count with RBC indices, iron profile ( serum iron, serum ferritine and total iron binding capacity) and HPLC Materials and Method-This hospital based cross sectional observational study was done on newly diagnosed cases anaemia in all age group except neonate. In each case CBC with RBC indices and RDW was measured by Automated cell counter ( SYSMEX KX21), serum iron profile was done by ELISA mehod and HPLC was done in BIORAD VARIANT-II. All results were analysed . Results and Analysis-Total 150 cases of microcytic hypochromic anemia were selected on the basis of above parameters and grouped as Group-1 ( iron deficiency anemia-IDA) cases 90 ( 60%), Group-2 ( anaemia on chronic disease-ACD ) cases 31 ( 21%) and Group-3 ( thalassaemia) cases 29 (19% ). Distribution of iron deficiency anaemia (IDA) predominantly (84%) was seen in female and in reproductive age (31-40 yrs) and in pre or post menopausal women (41-50 yrs). In Group-2 most of the cases of ACD was found in the elderiy age group who were suffering from various type of chronic illness. These age groups are mainly above 50 yrs and male predominant (74%). In Group-3, thalassemia group majority (55%) of the cases were from male children and found in age group of. 6-10 yrs . Conclusion-Iron deficiency anemia comprises the major cause of microcytic hypochromic anemia in a study of both rural and urban population of Bengal.
GLOBAL JOURNAL FOR RESEARCH ANALYSIS · 2024 · 0 citations · open access
A CLINICO-HEMATOLOGICAL PROFILE OF MICROCYTIC HYPOCHROMIC ANEMIA IN CHILDREN: AN OBSERVATIONAL STUDY
AbstractMicrocytic hypochromic anemia is anemia classication based on the morphology of anemia . The causes of microcytic hypochromic anemia may be either due to iron deciency anemia, anemia of inammation, or thalassemia. . To investigate the causes of Microcytic Hypochromic anaemia at a tertiary care centre in NALGONDA. After obtaining valid written consent, cases of microcytic hypochromic anaemia were selected from the OPD . The whole haematological and biochemical investigations were sent for anaemia workup. The study comprised 44 patients with microcytic hypochromic disorder. The study comprised subjects ranging in age from 1 TO 11 years. 42% were men and 58% were women. Anemia is not an illness in and of itself, but rather a symptom of another, hence nding the underlying cause is signicantly more important. The diagnosis of microcytic hypochromic anaemia is insufcient in the absence of an underlying cause. Special precautions will be made to determine the cause of iron decient anaemia. The thalassemia trait must also be diagnosed in order to minimise excessive iron supplementation and for family screening.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
